NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 110 filers reported holding NGM BIOPHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 1.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $22,063 | -58.7% | 20,619 | 0.0% | 0.00% | – |
| Q2 2023 | $53,403 | -27.0% | 20,619 | +15.0% | 0.00% | – |
| Q1 2023 | $73,174 | -22.1% | 17,935 | -4.1% | 0.00% | – |
| Q4 2022 | $93,889 | -49.0% | 18,703 | +33.2% | 0.00% | – |
| Q3 2022 | $184,000 | +8.9% | 14,046 | +6.5% | 0.00% | – |
| Q2 2022 | $169,000 | -45.0% | 13,190 | -9.8% | 0.00% | – |
| Q3 2021 | $307,000 | -8.4% | 14,628 | -13.9% | 0.00% | – |
| Q2 2021 | $335,000 | -24.7% | 16,999 | +11.2% | 0.00% | – |
| Q1 2021 | $445,000 | +3.2% | 15,291 | +7.6% | 0.00% | – |
| Q4 2020 | $431,000 | -44.8% | 14,214 | -71.0% | 0.00% | -100.0% |
| Q3 2020 | $781,000 | +20.2% | 49,078 | +49.1% | 0.00% | 0.0% |
| Q2 2020 | $650,000 | – | 32,919 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RHO CAPITAL PARTNERS INC | 3,766,666 | $79,175,000 | 44.14% |
| Ponoi II Management, LLC | 1,298,908 | $27,303,000 | 40.46% |
| Column Group LLC | 15,396,116 | $323,626,000 | 36.81% |
| Ponoi Management, LLC | 1,298,908 | $27,303,000 | 24.24% |
| Euclidean Capital LLC | 832,274 | $17,494,000 | 8.50% |
| StepStone Group LP | 1,573,357 | $33,072,000 | 2.14% |
| Octagon Capital Advisors LP | 200,000 | $4,204,000 | 1.04% |
| Redmile Group, LLC | 2,505,118 | $52,658,000 | 0.92% |
| BVF INC/IL | 955,000 | $20,074,000 | 0.78% |
| Boxer Capital, LLC | 500,000 | $10,510,000 | 0.37% |